

TDMs No. 20310 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 07/22/2009

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AZT)

Time Report Requested: 11:51:18

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C Number: C20310C

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 917 Vehicl PND 1-8 M Include 918 AZT 40 PND 1-8 M

Study Gender: Male

TDMSE Version: 2.1.0

Test Type: 26-39 WEEKS

Time Report Requested: 11:51:18

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M
---------------------------------------	------------------	------------------

Disposition Summary

Animals Initially in Study	24	25
Early Deaths		
Natural Death		1
Survivors		
Moribund Sacrifice	1	2
Terminal Sacrifice	23	22
Animals Examined Microscopically	24	25

ALIMENTARY SYSTEM

Intestine Large, Cecum	(24)	(24)
Hyperplasia, Lymphoid	3 [1.0]	1 [2.0]
Intestine Large, Rectum	(24)	(24)
Degeneration, Cystic	1 [2.0]	
Liver	(24)	(25)
Cytomegaly	18 [1.4]	14 [1.6]
Eosinophilic Focus		1
Inflammation, Chronic Active	1 [2.0]	1 [1.0]
Necrosis	2 [2.0]	1 [1.0]
Tension Lipidosis	3 [1.3]	2 [1.5]
Vacuolization Cytoplasmic	23 [1.7]	18 [1.6]
Pancreas	(23)	(25)
Cytoplasmic Alteration	1 [2.0]	
Salivary Glands	(24)	(25)
Infiltration Cellular, Lymphocyte	8 [1.0]	8 [1.0]

CARDIOVASCULAR SYSTEM

Blood Vessel	(24)	(24)
Heart	(24)	(25)

ENDOCRINE SYSTEM

Adrenal Cortex	(24)	(25)
Hypertrophy		1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:51:18

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle PND 1-8 M	AZT 40 PND 1-8 M
Subcapsular, Hyperplasia Islets, Pancreatic	7 [1.0] (23)	7 [1.0] (25)
Hyperplasia Thyroid Gland	1 [2.0] (24)	2 [2.0] (24)
Cyst Ectopic Thymus	1	1 [1.0]
GENERAL BODY SYSTEM		
Tissue NOS	(0)	(1)
GENITAL SYSTEM		
Epididymis	(24)	(24)
Hypospermia		1 [4.0]
Serosa, Inflammation, Chronic Active	1 [4.0]	
Serosa, Necrosis	1 [4.0]	
Preputial Gland	(24)	(24)
Abscess		1 [3.0]
Degeneration	1 [3.0]	
Duct, Dilatation		1 [3.0]
Prostate	(24)	(25)
Infiltration Cellular, Lymphocyte	1 [2.0]	1 [1.0]
Epithelium, Hyperplasia	1 [2.0]	
Seminal Vesicle	(24)	(25)
Serosa, Inflammation, Chronic Active	1 [2.0]	
Testes	(24)	(24)
Spermatocoele		1 [4.0]
Interstitial Cell, Hyperplasia	2 [1.0]	4 [1.0]
Seminiferous Tubule, Degeneration	2 [2.0]	2 [2.5]
HEMATOPOIETIC SYSTEM		
Bone Marrow	(24)	(25)
Myeloid Cell, Hyperplasia		2 [2.5]
Lymph Node, Mesenteric	(24)	(24)
Hyperplasia, Lymphoid	15 [1.6]	12 [1.4]
Spleen	(24)	(24)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:51:18

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle PND 1-8 M	AZT 40 PND 1-8 M
Depletion Lymphoid	1 [3.0]	
Hematopoietic Cell Proliferation	2 [2.0]	3 [3.0]
Hyperplasia, Lymphoid	5 [2.0]	7 [2.0]
Thymus	(23)	(22)
Degeneration	1 [1.0]	
Hyperplasia, Lymphoid		1 [2.0]
Necrosis		1 [2.0]
INTEGUMENTARY SYSTEM		
Skin	(24)	(25)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
Brain, Cerebrum	(24)	(25)
Mineralization	6 [1.0]	3 [1.0]
RESPIRATORY SYSTEM		
Lung	(24)	(25)
Foreign Body		1
Infiltration Cellular, Polymorphonuclear		1 [2.0]
Bronchiole, Epithelium, Hyperplasia		1 [2.0]
Nose	(24)	(25)
Foreign Body		1
Inflammation, Suppurative		1 [4.0]
SPECIAL SENSES SYSTEM		
Harderian Gland	(24)	(25)
URINARY SYSTEM		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:51:18

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle PND 1-8 M	AZT 40 PND 1-8 M
Kidney	(24)	(25)
Infiltration Cellular, Lymphocyte	6 [1.0]	6 [1.0]
Mineralization		1 [1.0]
Capsule, Inflammation, Chronic Active	1 [2.0]	
Pelvis, Dilatation		1 [2.0]
Renal Tubule, Regeneration	2 [1.0]	3 [1.0]
Urinary Bladder	(24)	(24)
Infiltration Cellular, Lymphocyte		1 [1.0]

*** END OF MALE ***

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)